treatment of neuroendocrine carcinoma
All entries for: AbbVie Inc.
March 2, 2026
AbbVie Inc.
Orphan Drug Designation
North Chicago, IL
50,001+ employees
Disease Area: Rare Diseases
February 20, 2026
AbbVie Inc.
Neutral Outlook
North Chicago, IL
50,001+ employees
The IRA has and will continue to meaningfully impact AbbVie’s business strategies and those of others in the pharmaceutical industry. The full impact of the IRA on AbbVie’s business and the pharmaceutical industry, including the implications to us of our or a competitor’s product being selected for price setting, remains uncertain.
Disease Area: Oncology
Drug Type: Biologic
February 20, 2026
AbbVie Inc.
Neutral Outlook
North Chicago, IL
50,001+ employees
In addition to the pricing mechanisms established under the IRA, governments and other payers may pursue or implement additional approaches intended to reduce pharmaceutical costs, including arrangements or frameworks that reference international prices, most-favored-nation (MFN) concepts, or other comparative pricing methodologies.